Surgery Partners, Inc. (SGRY)

In the past six months, Surgery Partners' stock experienced notable events and price movements. The stock reached a 52-week low of $14.02, declining by 45.52% over the past year due to financial performance and industry challenges. Key events include the Q3 2025 earnings report, which cited softer-than-expected same-facility volume growth and a shift in payer mix, leading to a downward revision of full-year guidance. The Q2 2025 earnings report showed strong growth in Adjusted EBITDA and revenue, with reaffirmed full-year guidance at that time. Surgery Partners announced plans to offer $425 million in senior unsecured notes due in 2032. Following a strategic review, the board decided to remain an independent, publicly traded entity. Wayne DeVeydt transitioned from Executive Chairman to join United Health Group as CFO.

Surgery Partners experiences demand seasonality, particularly affecting its cash flow. Operating cash flow is typically lower in the first quarter due to seasonal patterns and working capital timing. The company generally observes a seasonal lift in commercial volumes during the fourth quarter. The demand for Surgery Partners' services is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion. The company has seen strong volume growth across all core specialties, with gastrointestinal (GI) and musculoskeletal (MSK) procedures leading the way. Total joint replacement cases in ASCs have shown significant increases in case volume.

Surgery Partners, Inc. is a healthcare services company with a national network of outpatient surgical facilities. The company provides cost-effective solutions for surgical and related ancillary care as an alternative to traditional hospitals. Surgery Partners operates within the outpatient surgical industry, which is experiencing significant demand due to advancements in medical technology and a preference for minimally invasive procedures. The company offers a range of outpatient surgical procedures across various specialties and integrated ancillary services. They emphasize high-acuity procedures, such as total joint replacements.

Surgery Partners operates an extensive network across the United States, with over 180 locations in 33 states. This broad geographic reach allows the company to serve a diverse patient population and collaborate with a wide array of physicians and healthcare professionals, with a strong market presence in numerous metropolitan and suburban areas.

Surgery Partners aims to enhance patient quality of life through partnership and is committed to providing quality, compassionate, and personalized care. The company highlights strong patient satisfaction rates and physician retention trends. The company's reputation has been influenced by its financial performance and strategic decisions. The downward revision of full-year 2025 guidance due to softer late-quarter commercial trends and slower capital deployment could impact investor confidence. The decision to remain an independent public company signals management's belief in the company's long-term value creation. Regulatory tailwinds, such as proposed increases in outpatient rates and expansion of procedures eligible for ASC reimbursement by CMS, are seen as positive for the company and the broader ambulatory surgery center market.

Surgery Partners, Inc. has a concentrated ownership structure, with institutional investors holding the vast majority of shares. Bain Capital Private Equity, LP is the largest single shareholder, holding approximately 38.62%. Other major institutional owners include Janus Henderson Group Plc, Pentwater Capital Management LP, Fmr Llc, King Street Capital Management, L.P., Vanguard Group Inc, BlackRock, Inc., UBS Financial Services, Inc., Dimensional Fund Advisors Lp, and Clearbridge Investments, LLC. Individual ownership accounts for a smaller percentage, around 1.48%.